Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Safety

Mifepristone

Hawley Seeks Congressional Oversight of Mifepristone After FDA Offers No Timeline on Safety Review

The move follows a private FDA briefing that offered no timeline for its safety review.

Live Action Urges HHS and FDA to Suspend Mifepristone After Undercover Planned Parenthood Calls

Republicans Press Trump Administration to Halt Mail-Order Abortion Pills Crossing State Lines

Republicans Push to Restore In‑Person Rules for Abortion Pill at Fiery Senate Hearing

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

FDA Opens Mifepristone Safety Review as 20 States Vow to Defend Access

FDA Commissioner Pledges Safety Review of Abortion Pill Mifepristone